Investor Gilead Sciences Inc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Gilead Sciences Inc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-14 13G/A XLO / Xilio Therapeutics, Inc. 9,105,451 10,613,944
2025-08-12 13D/A 4,505,391
2025-07-15 13D/A RCUS / Arcus Biosciences, Inc. 39,691,649 31,424,760
2025-03-20 13G/A KLRS / Kalaris Therapeutics, Inc. 723,273
2025-03-05 13D/A RCUS / Arcus Biosciences, Inc. 39,691,649 39,691,649
2025-02-20 13D/A RCUS / Arcus Biosciences, Inc. 31,532,781 39,691,649
2025-02-13 13G/A IKNA / Ikena Oncology, Inc. 2,931,467 1,521,312
2025-01-10 13D/A GLPG / Galapagos NV - Depositary Receipt (Common Stock) 20,981,010 20,981,010
2024-12-23 13D/A 1,268,972 2,209,471
2024-12-19 13G/A XLO / Xilio Therapeutics, Inc. 7,345,473 9,105,451
2024-06-20 13D/A ASMB / Assembly Biosciences, Inc. 13,073,668 1,268,972
2024-05-02 13D/A GLPG / Galapagos NV - Depositary Receipt (Common Stock) 20,628,929 20,981,010
2024-04-19 13G LPTX / Leap Therapeutics, Inc. 5,319,148
2024-04-05 13G XLO / Xilio Therapeutics, Inc. 7,345,473
2024-02-20 13G KYTX / Kyverna Therapeutics, Inc. 4,126,119
2024-02-13 13G/A ALVR / AlloVir, Inc. 13,704,416 16,635,286
2024-02-13 13G/A TNGX / Tango Therapeutics, Inc. 4,854,443 4,854,443
2024-01-31 13D/A RCUS / Arcus Biosciences, Inc. 25,586,953 31,532,781
2023-12-28 13G/A ACLX / Arcellx, Inc. 3,478,261 6,720,803
2023-12-22 13G/A HOOK / HOOKIPA Pharma Inc. 3,759,465 18,759,465
2023-10-25 13D ASMB / Assembly Biosciences, Inc. 13,073,668
2023-10-19 13G IKNA / Ikena Oncology, Inc. 2,931,467
2023-07-06 13D/A RCUS / Arcus Biosciences, Inc. 22,723,156 25,586,953
2023-02-14 13G/A HOOK / HOOKIPA Pharma Inc. 3,759,465 3,759,465
2023-02-06 13G ACLX / Arcellx, Inc. 3,478,261
2022-08-08 13G ALVR / AlloVir, Inc. 13,704,416 13,704,416
2022-02-17 13G/A AGEN / Agenus Inc. 11,111,111 11,111,111
2022-02-17 13G/A HOOK / HOOKIPA Pharma Inc. 2,092,799 3,759,465
2022-02-10 13G/A SRRA / Sierra Oncology Inc 1,073,300 1,450,566
2022-02-10 13G AGEN / Agenus Inc. 11,111,111 11,111,111
2022-02-10 13G/A ALLO / Allogene Therapeutics, Inc. 7,486,689 1,156,689
2021-09-10 13G TNGX / Tango Therapeutics, Inc. 4,854,443
2021-02-12 13G/A HOOK / HOOKIPA Pharma Inc. 1,667,268 2,092,799
2021-02-02 13D/A RCUS / Arcus Biosciences, Inc. 29,498,424 22,723,156
2020-10-26 13G JNCE / Jounce Therapeutics Inc 5,539,727
2020-07-17 13D RCUS / Arcus Biosciences, Inc. 29,498,424
2020-02-14 13G/A HOOK / HOOKIPA Pharma Inc. 1,667,268 1,667,268
2020-02-10 13G SRRA / Sierra Oncology Inc 1,073,300
2019-11-01 13D/A GLPG / Galapagos NV - Depositary Receipt (Common Stock) 13,589,686 20,628,929
2019-08-29 13D/A GLPG / Galapagos NV - Depositary Receipt (Common Stock) 6,760,701 13,589,686
2019-07-23 13D GLPG / Galapagos NV - Depositary Receipt (Common Stock) 6,760,701 6,760,701
2019-05-03 13G HOOK / HOOKIPA Pharma Inc. 1,667,268
2019-02-13 13G ALLO / Allogene Therapeutics, Inc. 7,486,689
2019-01-29 13G AGEN / Agenus Inc. 11,111,111 11,111,111
2019-01-28 13G AGEN / Agenus Inc. 11,111,111
2018-03-08 13G/A GLPG / Galapagos NV - Depositary Receipt (Common Stock) 6,760,701 6,760,701
2016-01-27 13G GLPG / Galapagos NV - Depositary Receipt (Common Stock) 6,760,701